A Phase 1 Clinical Trial of NTQ5082 in Healthy Volunteers
Status:
NOT_YET_RECRUITING
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
NTQ5082 capsule is a small molecule CFB factor inhibitor. The study is a randomized, double-blind, placebo-controlled, dose escalation phase 1 clinical trial to evaluate the safety, tolerability and PK/PD characteristics of NTQ5082 capsules orally administered in healthy subjects in single and multiple doses.